ABSTRACT
Lung transplantation (LTx) has become a viable option for the end-stage lung disease because of its ability to prolong survival in patients with endstage lung diseases. In 1963, the first LTx recipient lived for 18 days postoperatively and died from renal failure (1). With improvements in surgical techniques, immunosuppression regimens, and long-term care, the current one-and five-year survival rates are 77% and 47%, respectively (2).
